177 results
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
be eligible for 12 years of market exclusivity upon approval in the US (independent of patents) and at least 10 years of market exclusivity upon approval in EU … (independent of patents) Platform Applications Formulation and Methods of Quantifying Nomlabofusp Platform Technology: Molecules for Protein Delivery
8-K
EX-99.2
eurdl36
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
PRE 14A
alczi98
12 Apr 24
Preliminary proxy
6:06am
S-8
EX-23.1
owtqly3y3f
14 Mar 24
Registration of securities for employees
5:07pm
S-8
bow knbmysarku2cg43
14 Mar 24
Registration of securities for employees
5:07pm
S-8
EX-5.1
el2xqz b7ml771
14 Mar 24
Registration of securities for employees
5:07pm
S-8
EX-23.1
z1vpwm
14 Mar 24
Registration of securities for employees
5:07pm
S-8
d60wy0aousr
14 Mar 24
Registration of securities for employees
5:07pm
S-8
EX-5.1
0mfdd8cu2x i3u2f
14 Mar 24
Registration of securities for employees
5:07pm